Pegloxenatide

DB19230InvestigationalProtein Based Therapies

Pegloxenatide is under investigation in clinical trial NCT05172999 (Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia).

Mechanism
Curator reviewed
Also known as
Peg loxenatide · Peg-40 kd-loxenatide · POLY(OXY-1,2-ETHANEDIYL), .ALPHA.-HYDRO-.OMEGA.-METHOXY-, 39,39-DIESTER WITH L-HISTIDYL-D-ALANYL-L-.ALPHA.-GLUTAMYLGLYCYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L-.ALPHA.-ASPARTYL-L-LEUCYL-L-SERYL-L-LYSYL-L-GLUTAMINYL-L-NORLEUCYL-L-.ALPHA.-GLUTAMYL · Polyethylene Glycol Loxenatide
Code names
PEX-168

Resolves to

Compound
UNIIBS678C7JWMCAS2420483-82-3
Targets
P43220GLP1R

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
9Clinical trialsPhase, status and sponsor resolved per trial
Sign in
5+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Pegloxenatide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In